The global cardiomyopathy market is anticipated to grow at a considerable CAGR of 4.2% during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace this is anticipated to hold significant growth. For instance, In April 2022, LianBio’s and Bristol-Myers Squibb partnered and developed Camzyos medicine which has been approved by U.S. Food and Drug Administration (FDA). This is developed for the treatment class II-III obstructive hypertrophic cardiomyopathy for cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Similarly, in November 2021, Sanofi has partnered with MyoKardia, both in partnership will develop and discover targeted therapeutics to treat patients with genetic heart disease. The partnership is mainly for three programs, in that two are focused on hypertrophic cardiomyopathy (HCM), while the other one is on dilated cardiomyopathy (DCM).
A full report of Cardiomyopathy Market is available at: https://www.omrglobal.com/industry-reports/cardiomyopathy-market
Furthermore, in May 2020, BioMarin Pharmaceutical Inc. and DiNAQOR AG collaborated to develop gene therapy to treat rare genetic cardiomyopathies. The new partnership is under DiNAQOR’s lead program in which DiNA-001 for MYBPC3 hypertrophic cardiomyopathy is being licensed. This is developing focused on the treatment of MYBPC3-linked cardiomyopathy. Whereas, in September 2019, Abbott has received FDA approval for its troponin blood test, which identifies heart attacks hours earlier than previous methods being used. Moreover, it has also launched a training partnership program to help the US hospital staff incorporate the automated blood test into their ER workflows and guide them about new tests developed.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiomyopathy-market
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Product
o By Technology
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Becton and Dickson & Co., Boston Scientific Corp., Mylan N.V, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Cardiomyopathy Market Report Segment
By Type
- Dilated Cardiomyopathy
- Restrictive Cardiomyopathy
- Unclassified Cardiomyopathy
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Dysplasia s
By Diagnosis Test
- Blood Tests
- Cardiac MRI
- Chest X-Ray
- Cardiac CT Scan
- Echocardiogram
- Treadmill Stress Test
- Electrocardiogram (Ecg)
- Cardiac Catheterization
- Genetic Testing or Screening
By Treatment
- Medication
- Nonsurgical Procedures
o Septal Ablation
o Radiofrequency Ablation
- Surgery
o Septal Myectomy
o Heart Transplant
By End-User
- Homecare
- Hospitals And Clinics
- Diagnostic Center
- Other
